For instance, T-DM1 combines the HER2-targeting monoclonal antibody trastuzumab with the cytotoxic agent emtansine (DM1) via a stable thioether linker, demonstrating effectiveness in HER2-positive BC and improved survival outcomes in clinical trials.16 The advent of anti-HER2 agents has significantly improved the prognosis of individuals with HER2-positive BC. This evidence concerns the gene ERBB2 and breast cancer.